GS967: Advanced Cardiac Late Sodium Current Inhibition for Arrhythmia Research

Executive Summary: GS967 is a highly potent and selective inhibitor of the cardiac late sodium current (late INa), with an IC50 of 0.13 μM in ventricular myocytes and 0.21 μM in isolated hearts, as reported in product documentation (APExBIO). Pathological elevation of late INa, often due to Nav1.5 Ser571 phosphorylation, contributes to delayed ventricular repolarization and diastolic dysfunction, especially in aging myocardium (Nav1.5 Ser571 Phosphorylation, Targeting INa,L in Aging). GS967 abolishes torsades de pointes (TdP) arrhythmias in ex vivo rabbit heart models and reduces MAPD90 without altering conduction time (product information). Comparative studies confirm that GS967's mechanism is distinct from non-selective sodium channel blockers, providing minimal use-dependence and robust efficacy in arrhythmia prevention research (GS967 in Electrophysiology). This article delivers protocol guidance, benchmarked findings, and clarifies common misconceptions regarding GS967’s application.

Biological Rationale

The cardiac late sodium current (INa,L) is a sustained Na⁺ influx persisting during the action potential plateau, arising when voltage-gated sodium channels (primarily Nav1.5) fail to fully inactivate (Targeting INa,L in Aging). Under physiological conditions, late INa constitutes only a minor component of the total sodium current. However, in pathological states such as heart failure, ischemia, oxidative stress, and congenital long QT3 syndromes, INa,L is markedly increased, contributing to arrhythmogenic substrate formation and impaired myocardial relaxation (Nav1.5 Ser571 Phosphorylation). Aging is associated with a ~60% increase in late INa in murine ventricular myocytes, correlating with a ~50% prolongation of the action potential duration at 90% repolarization (APD90) (Am J Physiol Heart Circ Physiol 2024).

Mechanism of Action of GS967

GS967 selectively inhibits the late sodium current by stabilizing the inactivated state of Nav1.5 channels, thereby reducing persistent Na⁺ influx during the plateau phase of the cardiac action potential (product information). GS967 demonstrates an IC50 of 0.13 μM in isolated ventricular myocytes and 0.21 μM in isolated hearts. The compound exhibits concentration- and voltage-dependent inhibition of peak INa with minimal use-dependence, distinguishing it from conventional, non-selective sodium channel blockers (Electrophysiology Applications). By reducing late INa, GS967 effectively prevents intracellular Na⁺ and Ca²⁺ overload, which are key mediators of arrhythmogenesis and contractile dysfunction in both experimental and clinical contexts (Targeting INa,L in Aging).

Evidence & Benchmarks

• GS967 abolishes ATX-II or E-4031-induced torsades de pointes (TdP) arrhythmias in isolated rabbit hearts (product information).
• In anesthetized rabbit models, GS967 reduces action potential duration at 90% repolarization (MAPD90) without significantly altering cardiac conduction time (product documentation).
• Late sodium current (INa,L) is increased by ~60% in aged murine myocytes compared to adults; inhibition of INa,L reverses prolonged QT interval and diastolic dysfunction (Am J Physiol Heart Circ Physiol 2024).
• Phosphorylation of Nav1.5 at Ser571 underlies pathological increases in late INa and drives age-related arrhythmogenesis and diastolic impairment (Nav1.5 Ser571 Phosphorylation).
• GS967 demonstrates greater selectivity and efficacy for late INa over peak INa compared to traditional sodium channel inhibitors, with minimal use-dependence (GS967: Cardiac Late Sodium Current Inhibitor).
• In vitro, GS967 reduces Na⁺ and Ca²⁺ overload, limiting arrhythmic triggers in both disease- and age-model systems (Targeting Cardiac Late Sodium Current in Aging).

Applications, Limits & Misconceptions

GS967 is widely used in in vitro cardiac electrophysiology and arrhythmia prevention research (GS967 Electrophysiology). Its selectivity supports precise modeling of late sodium current-driven disease phenotypes, particularly for studies of aging and congenital arrhythmia syndromes. GS967 is not recommended for diagnostic, clinical, or long-term solution storage applications (APExBIO).

Common Pitfalls or Misconceptions

• GS967 is not a pan-sodium channel blocker; its action is selective for late INa and shows minimal inhibition of peak INa at lower concentrations.
• It does not substitute for antiarrhythmic therapy in clinical settings; GS967 is intended solely for scientific research.
• GS967 is insoluble in water and requires DMSO or ethanol (with ultrasonic) for dissolution; improper solvent use can lead to precipitation and inconsistent dosing (product information).
• Prolonged storage of GS967 solutions is discouraged, as compound stability may decrease beyond recommended time frames.
• Not all arrhythmias are driven by late sodium current elevation; selectivity should be matched to the mechanistic hypothesis of the model system (GS967: Cardiac Late Sodium Current Inhibitor).

Workflow Integration & Parameters

• Compound dissolution: Dissolve GS967 in DMSO (≥13.35 mg/mL) or ethanol (≥25.52 mg/mL with ultrasonic); avoid water due to insolubility (APExBIO).
• Storage conditions: Store solid GS967 at -20°C; use freshly prepared solutions for each experiment.
• In vitro dosing: Benchmark IC50 values are 0.13 μM for ventricular myocytes; titrate concentration according to experimental objectives (product information).
• Arrhythmia model application: For ex vivo isolated heart protocols, GS967 effectively abolishes TdP when arrhythmias are induced by ATX-II or E-4031.
• Electrophysiology readouts: Monitor changes in APD90, Na⁺ and Ca²⁺ transient kinetics, and arrhythmic event frequency.

Conclusion & Outlook

GS967, as offered by APExBIO, presents a validated and selective approach for studying the role of late sodium current in cardiac dysfunction, with particular strengths in arrhythmia prevention research and age-related disease modeling. The evidence base supports its use in dissecting Nav1.5-mediated electrical and mechanical remodeling in the myocardium. As more is learned about the molecular regulation of INa,L—especially via Nav1.5 Ser571 phosphorylation—GS967 remains a critical tool for translational cardiac electrophysiology (Nav1.5 Ser571 Links Aging to Dysfunction). This article extends previous work by providing protocol parameters and clarifying the compound’s limits, supporting reproducible, high-impact arrhythmia studies.